Treatments

*November 2024* The first patients have been dosed in 3 phase 3 trials evaluating various combinations of datapotamab deruxtecan (Dato-DXd) for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC).1 TROPION-Lung10 (NCT06357533) is investigating Dato-DXd plus rilvegostomig (AZD2936), a PD-1/TIGIT bispecific antibody, or rilvegostomig alone vs pembrolizumab…

*October 2024* A phase 1/2 trial (NCT06567015) evaluating STX-241 (PFL-241) for the treatment of EGFR inhibitor-resistant non–small cell lung cancer (NSCLC) has dosed its first patient.1 "We are eager to begin the clinical evaluation of PFL-241/STX-241, our mutant-selective fourth generation EGFR inhibitor, a molecule with differentiated properties that we believe…

*November 2024* In this recorded webinar, oncologist and executive medical director, Dr. Julio Hajdenberg from Black Diamond Therapeutics joined Stage IV EGFR lung cancer patients Leah Phillips and Karly Renn to explore common misconceptions about clinical trials and highlight the critical role these trials play in advancing lung cancer treatment.…

*October 2024* This is the recorded webinar discussing how immune cells can be engineered to target EGFR+ NSCLC. This webinar featured Jill Feldman and Laura Book, members of the EGFR Resisters, and Dr. Alexandre Reuben from the MD Anderson Cancer Center. Dr. Reuben is a 2023 EGFR Resisters/LUNGevity Foundation grant…

*September 2024* Durable and substantial response rates were observed when BAY 2927088 was used to treat patients with pretreated HER2-mutant non–small cell lung cancer (NSCLC), according to results from cohort D of the phase 1 SOHO-01 trial (NCT05099172) presented at the 2024 IASLC World Conference on Lung Cancer (WCLC). The objective response…

*September 2024* Symptom progression was significantly delayed when patients with EGFR-mutated non–small cell lung cancer (NSCLC) were treated with amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) compared with osimertinib (Tagrisso) monotherapy, according to a presentation from the 2024 IASLC World Conference on Lung Cancer (WCLC).1 The study assessed the results observed in the phase…

*September 2024* Early efficacy and safety were reported with firmonertinib (AST2818; formerly furmonertinib) in those with non–small cell lung cancer (NSCLC) harboring EGFR P-loop and αC-helix compressing (PACC) mutations, according to findings from the phase 1b FURHTER trial presented at the IASLC 2024 World Conference on Lung Cancer (WCLC). “Firmonertinib has shown promising…

*September 2024* In this video, panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment strategies. Watch here.

*September 2024* In this video, Prof Ignacio Gil-Bazo (Catholic University of Valencia, Valencia, Spain), Dr Mariana Brandão (Institut Jules Bordet, Brussels, Belgium), Prof Benjamin Besse (Institut Gustave Roussy, Villejuif, France), and Prof Enriqueta Felip (Vall d'Hebron University Hospital, Barcelona, Spain) discuss the latest developments in treating EGFR mutated NSCLC, with…

*October 2024* In this video update, Dr Herbert H. Loong shares his perspective on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) to emerge from two important congresses, WCLC and ESMO 2024. Dr Loong reviews data from the following clinical trials (with corresponding video time stamps): 0:13 - TRUST-II…